Live Breaking News & Updates on Ikarian Capital

Stay updated with breaking news from Ikarian capital. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Wedbush Reiterates "Outperform" Rating for Aerovate Therapeutics (NASDAQ:AVTE)

Wedbush restated their outperform rating on shares of Aerovate Therapeutics (NASDAQ:AVTE – Free Report) in a research report report published on Wednesday, Benzinga reports. The brokerage currently has a $41.00 price target on the stock. AVTE has been the subject of a number of other reports. Wells Fargo & Company reissued an overweight rating and […] ....

United States , Georgea Eldridge , Hunter Gillies , Eventide Asset Management , Jefferies Financial Group , Ikarian Capital , Aerovate Therapeutics Inc , Wells Fargo Company , Vanguard Group Inc , Alps Advisors Inc , Aerovate Therapeutics , Free Report , Financial Group , Therapeutics Stock Down , Get Free Report , Asset Management , Point Capital , Alps Advisors , Aerovate Therapeutics Daily ,

Protara Therapeutics, Inc. (NASDAQ:TARA) Major Shareholder Sells $100,980.00 in Stock

Protara Therapeutics, Inc. (NASDAQ:TARA – Get Free Report) major shareholder Opaleye Management Inc. sold 33,000 shares of the stock in a transaction dated Tuesday, May 21st. The shares were sold at an average price of $3.06, for a total transaction of $100,980.00. Following the sale, the insider now directly owns 124,250 shares of the company’s […] ....

Opaleye Management Inc , Exchange Commission , Ikarian Capital , Securities Exchange Commission , Protara Therapeutics Company Profile , Protara Therapeutics Inc , Protara Therapeutics , Get Free Report , Opaleye Management , Free Report , Protara Therapeutics Daily ,

BiomX (NYSEMKT:PHGE) Rating Reiterated by HC Wainwright

HC Wainwright restated their buy rating on shares of BiomX (NYSEMKT:PHGE – Free Report) in a research note issued to investors on Tuesday morning, Benzinga reports. The brokerage currently has a $2.00 target price on the stock. HC Wainwright also issued estimates for BiomX’s Q2 2024 earnings at ($0.12) EPS, Q3 2024 earnings at ($0.13) […] ....

Biomx Inc , Exchange Commission , Ikarian Capital , Free Report , Get Free Report , Biomx Daily ,

Q32 Bio (NASDAQ:QTTB) Earns Outperform Rating from Analysts at SVB Leerink

Research analysts at SVB Leerink initiated coverage on shares of Q32 Bio (NASDAQ:QTTB – Get Free Report) in a note issued to investors on Tuesday, Briefing.com reports. The brokerage set an “outperform” rating and a $54.00 price target on the stock. SVB Leerink’s price objective would indicate a potential upside of 78.81% from the company’s […] ....

Piper Sandler , Capital Management , Bio Inc , Vanguard Group Inc , Acadian Asset Management , Affinity Asset Advisors , Ikarian Capital , Get Free Report , Stock Down , Asset Management , Asset Advisors , Vanguard Group ,